Skip to main content
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
Easy-to-follow guides
Independent reviews
Vetted providers
Free to read

Home / Peptide legality / Kansas

Peptide legality · Kansas · updated 2026-09-21

Are peptides legal in Kansas?

Gray area

Kansas has no peptide-specific prohibition, so peptide legality in Kansas defers to the federal compounding framework, making the honest verdict gray rather than clearly legal or illegal.

Legal status overview

Kansas is a gray-zone state because it regulates peptides through general compounding law rather than any peptide-specific statute. FDA-approved products such as Wegovy® (semaglutide) are legal by prescription, while research peptides like BPC-157 remain neither FDA-approved nor authorized for compounding. Kansas compounding standards live in K.A.R. Article 13, and House Bill 2068 will formally adopt the USP 795, 797, and 825 chapters under the Kansas Pharmacy Act effective July 1, 2027. This is general information, not legal or medical advice.

Key points

  • Kansas has no statute that names or bans peptides specifically; the Kansas State Board of Pharmacy regulates them through its compounding rules and the underlying federal 503A framework. [3]
  • Minimum standards for sterile and nonsterile compounding in Kansas are set by K.A.R. 68-13-2, 68-13-3, and 68-13-4, with K.A.R. 68-13-4 covering sterile preparations compounded in or shipped into Kansas. [4]
  • House Bill 2068 adopts the USP 795, 797, and 825 compounding standards under the Kansas Pharmacy Act effective July 1, 2027, and the Board is drafting Article 13 amendments to match USP. [6]
  • The FDA removed BPC-157 and eleven other peptides from the Category 2 do not compound list on April 15, 2026, but did not add them to the Category 1 authorized bulk substances list, so they remain in a regulatory gray zone. [1]
  • Removal from Category 2 does not authorize compounding; a bulk substance still needs Category 1 status, FDA approval, or a USP monograph, none of which BPC-157 has. [2]
  • Wegovy® (semaglutide) and Zepbound® (tirzepatide) are FDA-approved and available by prescription in Kansas; compounded semaglutide and compounded tirzepatide are not FDA-approved, are not a generic, and have not been evaluated by the FDA, and broad compounding largely ended after the 2025 shortage resolutions. [2]
  • Kansas statute K.S.A. 65-1637 sets the requirements for prescription orders and for compounding, filling, and refilling prescriptions in the state. [5]
  • Somatropin (human growth hormone) is restricted nationwide by 21 U.S.C. 333(e), which limits distribution to FDA-approved indications, so anti-aging or performance use is prohibited in Kansas. [7]

Compound-by-compound status

BPC-157
Gray area
Not FDA-approved and no USP monograph. Removed from the FDA Category 2 do not compound list on April 15, 2026, but not added to the Category 1 authorized list, so it remains a gray-zone substance in Kansas as elsewhere.
GLP-1 class (semaglutide, tirzepatide)
Restricted
Wegovy® (semaglutide), Ozempic® (semaglutide), Zepbound® (tirzepatide), and Mounjaro® (tirzepatide) are FDA-approved and available by prescription in Kansas. Compounded semaglutide and compounded tirzepatide are not FDA-approved, are not a generic, and have not been evaluated by the FDA; broad compounding was curtailed after the 2025 shortage resolutions.
TB-500 (thymosin beta-4 fragment)
Gray area
Not FDA-approved and no USP monograph. Removed from Category 2 on April 15, 2026, but not authorized for compounding, so it sits in the same gray zone as BPC-157 in Kansas.
Growth hormone / somatropin
Restricted
A prescription drug whose distribution is limited by 21 U.S.C. 333(e) to FDA-approved indications ordered by a physician. Distribution for anti-aging, bodybuilding, or general wellness is a federal crime and applies in Kansas.

Frequently asked questions

Are peptides legal in Kansas?

Kansas has no law that bans peptides by name. FDA-approved peptide drugs are legal by prescription, but research peptides such as BPC-157 are neither FDA-approved nor authorized for compounding, which leaves them in a gray zone. This is general information, not legal advice.

Can a Kansas pharmacy compound BPC-157?

Not lawfully as a bulk substance today. The FDA removed BPC-157 from the Category 2 list in April 2026 but did not add it to the Category 1 authorized list, and it has no USP monograph and no FDA approval, so it is not cleared for 503A compounding.

What compounding standards apply in Kansas?

Kansas compounding sits in K.A.R. Article 13, including K.A.R. 68-13-4 for sterile preparations. House Bill 2068 will adopt the USP 795, 797, and 825 chapters under the Kansas Pharmacy Act effective July 1, 2027.

Is compounded semaglutide available in Kansas?

Wegovy® (semaglutide) and Ozempic® (semaglutide) are FDA-approved and available by prescription. Compounded semaglutide is not FDA-approved, is not a generic, and has not been evaluated by the FDA, and broad compounding largely ended after the 2025 shortage resolutions.

Is human growth hormone legal for anti-aging in Kansas?

No. Federal law at 21 U.S.C. 333(e) limits somatropin distribution to FDA-approved indications, and the FDA treats writing a prescription as distribution, so anti-aging or performance use is prohibited nationwide, including Kansas.

General information based on the sourced research above, not legal advice. For a specific situation in Kansas, consult a licensed attorney familiar with pharmaceutical law.